Advertisement

Topics

After 2 Patient Deaths, FDA Imposes Partial Clinical Hold on Trial of Xencor Blood Cancer Antibody XmAb14045

10:15 EST 20 Feb 2019 | Genetic Engineering News

Xencor acknowledged today that the FDA has placed the company’s Phase I trial of its CD123 x CD3 bispecific antibody XmAb®14045 on a partial clinical hold following the deaths of two patients linked to the blood cancer candidate. Xencor said one patient experienced cytokine release syndrome (CRS) after their first dose, “the treatment of which […]

The post After 2 Patient Deaths, FDA Imposes Partial Clinical Hold on Trial of Xencor Blood Cancer Antibody XmAb14045 appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: After 2 Patient Deaths, FDA Imposes Partial Clinical Hold on Trial of Xencor Blood Cancer Antibody XmAb14045

NEXT ARTICLE

More From BioPortfolio on "After 2 Patient Deaths, FDA Imposes Partial Clinical Hold on Trial of Xencor Blood Cancer Antibody XmAb14045"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...